5 November 2025 - Rhythm Pharmaceuticals today announced that it has entered into Product Listing Agreements in the provinces of Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and with the Federal Non-Insured Health Benefits Program for the public reimbursement of Imcivree for weight management in eligible adult and paediatric patients aged 6 years and older with clinically or genetically confirmed Bardet-Biedl syndrome and obesity.

Imcivree was approved by Health Canada in May 2023 following priority review and was recently added to the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases.

Read Rhythm Pharmaceuticals press release